Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A new health economic measure for improving the health and wellbeing of older Australians in subacute care settings: a study protocol.

BMC geriatrics·2026
Same author

A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The Neuropsychiatric Symptom Profile of Mild Dementia With Lewy Bodies.

Journal of geriatric psychiatry and neurology·2026
Same author

Strength together: Risk and protective factors for dementia and cognitive impairment in Aboriginal and Torres Strait Islander peoples.

International psychogeriatrics·2026
Same author

Implementing interpreter training for dementia assessments at national scale using the RE-AIM framework: a mixed-methods evaluation.

BMC geriatrics·2026
Same author

CloneCoordinate: Open-Source Software for Collaborative DNA Construction.

ACS synthetic biology·2025
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Jian Xiang Ding1, Oneil G Bhalala1,2, Kai Sin Chin1,2

  • 1The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

在临床环境中,招募痴呆症血液生物标志物研究是可行的. 务实的设计和最小的排斥成功地招募了各种各样的参与者,包括老年人和来自不同文化背景的人.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 临床试验 临床试验

背景情况:

  • 为痴呆症临床研究招募患者面临挑战,特别是在老年人群和文化和语言多样性 (CALD) 的人群中.
  • 这项研究通过在公共医院记忆诊所建立血液生物标志物队列来解决这些挑战.

研究的目的:

  • 描述正在进行的血液生物标志物队列研究的建立和早期招募经验.
  • 评估招募各种患者群体用于痴呆症研究的可行性.

主要方法:

  • 从2023年10月起,招聘发生在皇家墨尔本医院的认知,痴呆和记忆服务 (CDAMS) 诊所.
  • 使用了广泛的纳入标准,包括那些需要口译员或决策者的人,以及为期12个月的远程医疗随访.
  • 采集了血液样本,以分析血神经丝光链和-tau-217.

主要成果:

  • 在200名参与者中,招募了73名,同意率为90%.
  • 该队伍的平均年龄为78岁,其中63%是女性.
  • 21%的参与者来自CALD背景.

结论:

  • 痴呆症血液生物标志物研究在临床环境中使用实用设计是可行的.
  • 尽量减少排斥标准和访问负担,有助于招募多样化,临床相关的人群.